Radiation Oncology Journal10.3857/roj.2012.30.3.1242012303124Treatment outcome in patients with triple negative early stage breast cancers compared with other molecular subtypesJa Young Kim, Sei-Kyung Chang, Heily Park, Bo-Mi Lee, Hyun Soo Shin,,
The Breast10.1016/s0960-9776(19)30135-3201944S27Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies,
The Breast10.1016/j.breast.2010.02.0032010193246-248Cisplatin–gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patientsNebu Koshy, Dolly Quispe, Runhua Shi, Richard Mansour, Gary V. Burton,
The Breast Journal10.1111/j.1524-4741.2012.01241.x2012183286-288Early Stage Triple Negative and HER2 Overexpression Breast Cancers Have Similar Survivals in Chinese PatientsQin Zhang, Shou-Ching Tang, Hong Liu,
Clinical Breast Cancer10.3816/cbc.2009.n.01820099296-100Outcome After Breast Conservation Treatment with Radiation for Women with Triple-Negative Early-Stage Invasive Breast CarcinomaLawrence J. Solin, Wei-Ting Hwang, Neha Vapiwala,
Annals of Oncology10.1016/j.annonc.2022.03.081202233S15265P Evaluation of survival outcome of adjuvant chemoradiotherapy compared to other treatment modalities stratified by tumor size in T1N0M0 triple-negative breast cancerA. Ellaithy,
Tumor Biology10.1177/10104283198470812019415101042831984708Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancerAnniina Jääskeläinen, Arja Jukkola, Juha Risteli, Kirsi-Maria Haapasaari, Peeter Karihtala,,
PLOS ONE10.1371/journal.pone.01293562015106e0129356Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future TherapyLamis Yehia, Fouad Boulos, Mark Jabbour, Ziyad Mahfoud, Najla Fakhruddin, Marwan El-Sabban
The Breast10.1016/j.breast.2021.12.018202262S29-S33Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 updateLauren C. Brown, Sherene Loi,
The Lancet Oncology10.1016/s1470-2045(19)30158-52019207e390-e396Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancersLajos Pusztai, Julia Foldi, Arjun Dhawan, Michael P DiGiovanna, Eleftherios P Mamounas,